$5.75
0.61% today
Nasdaq, Sep 15, 07:42 pm CET
ISIN
CA29286M1059
Symbol
ENGN

EnGene Stock price

$5.71
+2.07 56.87% 1M
+0.42 7.94% 6M
-0.94 14.14% YTD
-0.94 14.14% 1Y
-4.37 43.35% 3Y
-4.15 42.09% 5Y
-4.15 42.09% 10Y
-4.15 42.09% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.35 5.78%
ISIN
CA29286M1059
Symbol
ENGN
Industry

Key metrics

Basic
Market capitalization
$291.8m
Enterprise Value
$98.0m
Net debt
positive
Cash
$217.4m
Shares outstanding
51.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
87.6%
Return on Equity
-20.2%
ROCE
-35.4%
ROIC
-188.3%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-87.6m | $-114.2m
EBIT
$-88.0m | $-113.4m
Net Income
$-79.9m | $-103.9m
Free Cash Flow
$-76.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-97.1% | -84.3%
EBIT
-96.4% | -82.0%
Net Income
30.7% | -88.4%
Free Cash Flow
-61.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.5
Short interest
0.0%
Employees
57
Rev per Employee
$0.0
Show more

Is EnGene a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

EnGene Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a EnGene forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a EnGene forecast:

Buy
88%
Hold
12%

Financial data from EnGene

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
27% 27%
-
- Research and Development Expense 63 63
151% 151%
-
-88 -88
97% 97%
-
- Depreciation and Amortization 0.37 0.37
12% 12%
-
EBIT (Operating Income) EBIT -88 -88
96% 96%
-
Net Profit -80 -80
31% 31%
-

In millions USD.

Don't miss a Thing! We will send you all news about EnGene directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EnGene Stock News

Neutral
Business Wire
4 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. “Reaching target enrollment in LEGEND's pivotal Cohort 1 and securing RMAT designation are important milestones that mark our continue...
Neutral
Seeking Alpha
5 days ago
enGene Holdings Inc. (NASDAQ:ENGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Ronald H. Cooper - President, CEO & Director Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome to the session of the Morgan Stanley Global Healthcare Conference.
Neutral
Business Wire
12 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid (“detalimogene” and previously EG-70) in patients with...
More EnGene News

Company Profile

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Head office Canada
CEO Ronald Cooper
Employees 57
Founded 2023
Website engene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today